- Home
- EGY vs ORIC Comparison
EGY vs ORIC Comparison
Compare EGY & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- ORIC
- Stock Information
- Founded
- EGY 1985
- ORIC 2014
- Country
- EGY United States
- ORIC United States
- Employees
- EGY N/A
- ORIC N/A
- Industry
- EGY Oil & Gas Production
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- ORIC Health Care
- Exchange
- EGY Nasdaq
- ORIC Nasdaq
- Market Cap
- EGY 340.3M
- ORIC 362.9M
- IPO Year
- EGY N/A
- ORIC 2020
- Fundamental
- Price
- EGY $3.48
- ORIC $4.77
- Analyst Decision
- EGY Strong Buy
- ORIC Strong Buy
- Analyst Count
- EGY 1
- ORIC 9
- Target Price
- EGY $8.00
- ORIC $18.43
- AVG Volume (30 Days)
- EGY 1.2M
- ORIC 969.8K
- Earning Date
- EGY 05-06-2025
- ORIC 05-05-2025
- Dividend Yield
- EGY 7.17%
- ORIC N/A
- EPS Growth
- EGY N/A
- ORIC N/A
- EPS
- EGY 0.56
- ORIC N/A
- Revenue
- EGY $478,988,000.00
- ORIC N/A
- Revenue This Year
- EGY N/A
- ORIC N/A
- Revenue Next Year
- EGY $23.00
- ORIC N/A
- P/E Ratio
- EGY $6.24
- ORIC N/A
- Revenue Growth
- EGY 5.26
- ORIC N/A
- 52 Week Low
- EGY $3.00
- ORIC $3.90
- 52 Week High
- EGY $7.43
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- EGY 46.12
- ORIC 37.10
- Support Level
- EGY $3.22
- ORIC $3.90
- Resistance Level
- EGY $3.44
- ORIC $5.38
- Average True Range (ATR)
- EGY 0.22
- ORIC 0.53
- MACD
- EGY 0.01
- ORIC 0.06
- Stochastic Oscillator
- EGY 56.47
- ORIC 41.97
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.